Stryker Corporation $SYK Stock Position Lessened by AHL Investment Management Inc.

AHL Investment Management Inc. cut its stake in Stryker Corporation (NYSE:SYK) by 14.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,900 shares of the medical technology company’s stock after selling 1,820 shares during the quarter. Stryker comprises about 2.8% of AHL Investment Management Inc.’s holdings, making the stock its 10th largest position. AHL Investment Management Inc.’s holdings in Stryker were worth $4,029,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Cresset Asset Management LLC increased its holdings in Stryker by 20.1% during the 1st quarter. Cresset Asset Management LLC now owns 21,313 shares of the medical technology company’s stock worth $7,952,000 after acquiring an additional 3,568 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in Stryker by 17.1% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 26,599 shares of the medical technology company’s stock worth $9,902,000 after acquiring an additional 3,883 shares during the period. Brooklyn Investment Group lifted its stake in Stryker by 8.5% in the 1st quarter. Brooklyn Investment Group now owns 3,092 shares of the medical technology company’s stock worth $1,151,000 after purchasing an additional 243 shares in the last quarter. Finally, Aptus Capital Advisors LLC boosted its holdings in Stryker by 8.9% in the 1st quarter. Aptus Capital Advisors LLC now owns 100,987 shares of the medical technology company’s stock valued at $37,592,000 after purchasing an additional 8,272 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.4%

Shares of SYK stock opened at $355.34 on Tuesday. The business has a 50-day moving average of $366.60 and a 200 day moving average of $378.26. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The stock has a market capitalization of $135.89 billion, a PE ratio of 46.69, a P/E/G ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is 44.15%.

Insider Buying and Selling at Stryker

In other news, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 522,118 shares of company stock worth $185,381,932. 5.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SYK shares. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. UBS Group set a $408.00 target price on Stryker in a research report on Monday, October 13th. Citigroup lowered their price target on Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday. Redburn Partners set a $420.00 price target on Stryker in a research report on Thursday, September 18th. Finally, Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday. Twelve equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $431.83.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.